-49.6%
ZTS vs MRNA
+511.3%
-560.9%
-52.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.6% | -2.2% | +1.6% | -0.6% |
| 7D | -2.0% | +5.5% | -7.5% | -2.1% |
| 30D | +1.9% | +158.7% | -156.8% | -2.5% |
| 3M | -4.0% | +182.1% | -186.1% | -9.4% |
| 6M | -39.1% | +151.8% | -190.9% | -42.0% |
| YTD | -38.8% | +393.6% | -432.4% | -45.6% |
| 1Y | -49.6% | +499.5% | -549.0% | -57.2% |
| All | -49.6% | +511.3% | -560.9% | -57.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling